-- MA Financial Group（ASX：MAF）週二向澳洲證券交易所提交的文件顯示，其第一季資產管理規模（AUM）年增44%，達到148億澳元。 截至3月31日的第一季，總資產管理規模較上年同期下降3%，主因是先前已公佈的Marion購物中心出售計畫。該公司預計該計劃對2026年的營收影響甚微。 該公司表示，包括機構資金在內的總資金流入量為4.9億澳元，低於去年同期的7.79億澳元。 文件也顯示，截至2月28日，Finsure管理的貸款年增27%，達到1,790億澳元，其中3月份的月度貸款申請總額創下110億澳元的歷史新高。
Related Articles
Asia
Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%
Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.
$SHA:600930
Asia
National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme
National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.
$ASX:NSR
Asia
Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%
Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.
$ASX:SPL